A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
SHIONOGI B.V.
Cita
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy. (2138P2231). SHIONOGI B.V. 2023IP:JOSÉ IGNACIO TEMBL FERRAIRO.
Portal de investigación